Longer-term data bolster Nektar Therapeutics’ bempegaldesleukin, but things haven’t changed that much since its last disappointment.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.